duvelisib + SG001

**Duvelisib + SG001** is a combination regimen of two drugs: duvelisib, an oral dual inhibitor of phosphatidylinositol 3-kinase δ and γ (PI3K-δ,γ), and SG001, an injectable agent under investigation. Used together primarily in patients with advanced solid tumors who have failed prior PD-1/PD-L1 therapies, this regimen aims to exploit the immunomodulatory and anti-tumor properties of both compounds. Duvelisib inhibits key signaling pathways implicated in cancer cell proliferation and survival, while SG001's mechanism is not fully characterized in public sources but is being evaluated for potential synergistic effects with duvelisib[1][3]. The drugs are administered in combination as part of clinical trials for advanced solid tumors.

Other names

duvelisib + SG001